MedTrace Logo

Identification of PAthways of Kinase Inhibitors TOxicity

NCT03896139 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2019-03-29

No results posted yet for this study

Summary

The investigators are identifying clinical diagnoses and toxicities associated with kinase inhibitors prescription. This identification will be applied will be applied in an electronic-health-record (EHR) cohort including North American and European.

Conditions

  • Kinase Inhibitors Toxicity

Interventions

DRUG

Kinase inhibitor

Patients treated with kinase inhibitors for cancer or other conditions

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    collaborator OTHER

  • Groupe Hospitalier Pitie-Salpetriere

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2019-03-01
Completion
2019-03-01
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03896139 on ClinicalTrials.gov